• Starling Medical

  Participated · Seed · Jan 2023

  StarStream is a reusable device that mounts on a toilet and directly analyzes urine samples, linking AI‑driven digital health analysis to a mobile app that notifies clinicians when issues are detected. The platform is described by CEO Alex Arevalos as "the world's first FDA‑registered service" and was developed as Starling Medical's second urinalysis product after an earlier catheter device. Starling completed a clinical trial with Stanford University to validate its prediction models and has been working on the technology for the past year. The company plans to expand detection to dozens of additional health disorders detectable in urine, including preeclampsia, diabetes‑related renal disease, and other conditions to reduce hospitalizations. Financially, Starling closed an initial $3.4M investment round and plans to use proceeds to hire engineers, build the device and software, and support hospital reimbursement workflows. The Houston‑based team has 10 employees and will roll the device out first with a Texas private clinic serving 200,000 urological patients. Starling Medical is developing an at-home urine diagnostic remote patient monitoring (RPM) platform that integrates into a user's bathroom routine. The system uses mass spectrometry–based sensors to monitor changes in a patient's urine over time. The company says its RPM service aims to lower hospitalization rates for chronic conditions such as recurrent urinary tract infections and diabetes. Starling emphasizes noninvasive, routine monitoring to inform care and early intervention. The announcement highlights backing from Y Combinator (YC W22) and thanks multiple institutional supporters and investors. The post focused on product and supporters rather than providing financial or operating metrics.

No current team members are available.